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Background/Purpose: Few clinical trials have investigated the antidiabetic effects of ginger to date.
Several recent clinical trials published in 2013 and 2014, although small, have added contradictory but
compelling new evidence about the use of ginger in treating diabetes in humans. Therefore, a systematic
review and meta-analysis was conducted to clarify the evidence for using ginger to treat diabetes.
Methods: Five randomized clinical trials (RCTs) were identiﬁed and included in the meta-analysis. Four of
the RCTs were considered high quality and lasted 8 weeks; one lasted only 30 days and was considered
low quality. Outcomes measured included fasting blood glucose and insulin, homeostatic model
assessment (HOMA)-insulin resistance (IR), and hemoglobin A1c (HbA1c) levels, and were assessed as
mean differences in the meta-analysis.
Results: Ginger supplementation signiﬁcantly lowered fasting blood glucose concentrations and HbA1c
levels, but did not signiﬁcantly lower fasting blood insulin or HOMA-IR.
Conclusion: Ginger root supplementation signiﬁcantly lowers blood glucose and HbA1c levels. When
combined with dietary and lifestyle interventions it may be an effective intervention for managing Type
2 diabetes mellitus.
Copyright © 2015, Korea Food Research Institute, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ginger, the rhizome of the plant Zingiber ofﬁcinale, is indigenous
to Southeast Asiawhere its cultivation dates back about 3,000 years
in India. Today its use has spread tomost of the inhabitedworld [1].
Ginger remains an integral part of Indian cuisine where it is
commonly used in many popular dishes. In Korea, ginger has been
used to season foods for the last 1,000 years approximately. Sliced
ginger with sugar added is used to make tea, pickled ginger slices
(Gari) are frequently used as a condiment in Japan, and ginger is
commonly used to ﬂavor cookies and cakes in Western countries
[2]. Almost simultaneous with its cultivation as a spice, ginger was
incorporated into Indian traditional Ayurvedic medicine and today
it is used a common herbal treatment for nausea in both Asian and
Western countries.
The prevalence of diabetesmellitus is high and rising worldwide
due to the global increases in obesity and unhealthy lifestyles. TheNutrition, Obesity/Diabetes
aeBang-Yup Asan-Si, Chung-
titute, Published by Elsevier. This isglobal prevalence of diabetes was reported to be 382million people
in 2013 and is expected to rise to 592 million by 2035. Type 2
diabetes makes up about 85% of cases of diabetes, with the other
15% attributed to Type 1 diabetes mellitus and gestational diabetes
[3]. Type 2 diabetes is a metabolic disorder that is characterized by
hyperglycemia in the context of insulin resistance and relative lack
of insulin [4,5]. Several types of drugs such as sulfonylurea, thia-
zolidinedione, incretin, and dipeptidyl-peptidase 4 inhibitors have
been prescribed for treating hyperglycemia in Type 2 diabetic pa-
tients. These drugs work by reducing insulin resistance and
improving insulin secretion capacity [5]. However, each drug has
adverse side-effects, so there is great interest in developing natural
interventions for managing diabetes and its symptoms [5].
Ginger contains various potentially bioactive substances such as
gingerols, shogaols, zingerone and paradol. It also includes volatile
oils such as sesquiterpenes [b-bisabolene and ()-zingiberene],
geranial, and neral [6]. Among gingerols and shogaol the major
pungent components in the rhizome are 6-gingerol and 6-shogaol
[6]. Ginger has long been used as an herbal medicine to treat
various symptoms including vomiting, pain, and cold symptoms,
and it has been shown to have anti-inﬂammatory, antidiabetic,
anticlotting and analgesic properties [7]. The data for thean open access article under the CC BY-NC-ND license (http://creativecommons.org/
J.W. Daily et al. / Journal of Ethnic Foods 2 (2015) 36e43 37bioavailability of ginger are limited. The major components of
ginger, 6-shogaol, 10-gingerol, 6-gingerol, and 8-gingerol, can be
detected in the plasma of rats and humans 1 hour after its oral
consumption [8,9]. At 48e60 hours after oral consumption of
ginger, 6-gingerol and 6-shogaol are excreted, mainly into the bile
and some into the urine [8]. Thus, the components of ginger are
absorbed into the body where they can exert various activities. The
safety of ginger has been investigated. Acute and chronic toxicity
studies have demonstrated the broad safety of ginger [10e12]. The
LD50 of methanol and water extracts of ginger was 10.25 g/kg and
11.75 g/kg body weight by oral administration in mice [11].
Administration of ginger powder up to 2 g/kg body weight/day did
not cause mortality or abnormal changes in hematological pa-
rameters in rats [12]. Thus, if ginger is shown to be effective in
alleviating hyperglycemia it can be safely used for its treatment.
As several randomized clinical trials (RCTs) examining ginger
supplementation have been recently conducted in Type 2 diabetic
patients, this study aims to carry out a systematic review of the use
of ginger for alleviating hyperglycemia.
2. Methods
2.1. Data sources and selection criteria
The following electronic databases were searched: PubMed,
EMBASE, the Cochrane Library, Korean database such as: DBpia, the
Research Information Service System, and the Korean Studies Infor-
mation Service System, Chinesemedical databases such as: the China
National Knowledge Infrastructure and the Chinese Scientiﬁc Jour-
nals Database, the Indian Medical Journals, and Indian Journals.
Dissertations were also included. The following search strategy was
used: (“ginger” or “Zingiber ofﬁcinale”) and (“diabetes” or “hyper-
glycemia” or “insulin”). All RCTs that studied the effects of ginger on
diabetic symptoms including serum glucose and insulin levels, he-
moglobin A1c (HbA1c), and homeostaticmodel assessment (HOMA)-
insulin resistance (IR) index in Type 2 diabetic patients were
included. Studies that investigated the antidiabetic effects of complex
herbal remedies that included ginger as an ingredientwere excluded.
2.2. Data extraction, quality and validity assessment
The data search was conducted in English, Korean, and Chinese
language databases using the following keywords of mesh termi-
nology: ginger, serum glucose levels, serum insulin levels, and Type
2 diabetes. Three independent reviewers screened the papers. In
the ﬁrst screening the related papers were identiﬁed by the titles
and abstracts of the papers and the relevant articles were retrieved
in full text and validated for inclusion in the systematic review. The
fourth reviewer independently validated the selected the papers.
2.3. Eligibility criteria for studies in this review
All prospective RCT studies about using ginger consumption for
the treatment of hyperglycemia in Type 2 diabetic patients were
included in this systematic review. Although no language barriers
were imposed, all studies included in this review were written in
English. Dissertations were included. Case studies, case series,
qualitative studies, and uncontrolled trials were excluded.
2.4. Patients and intervention
This systematic review included all RCTs that investigated the
effects of ginger powder on the treatment of hyperglycemia in Type
2 diabetic patients. The eligibility of participants was somewhat
different among individual studies; however, in all of the studiesthe participants had Type 2 diabetes for at least 2e10 years and had
no serious diabetic complications. Furthermore, they did not have
acute inﬂammatory diseases, did not smoke or drink, and none
were pregnant or lactating. In all RCTs powder of dried ginger was
orally consumed at different dosages (1.6e3 g/day) and for different
durations (30e84 days).
2.5. Quality assessment of the articles
The Cochrane tool was used to assess quality of the RCT articles
included in this systematic review by determining the risk of bias
(ROB) [13]. This validated tool consisted of the following six cate-
gories: (1) random sequence generation; (2) allocation conceal-
ment; (3) blinding of participants; (4) incomplete outcome data;
(5) selective outcome reporting; and (6) other bias. Each category
was scored as high ROB, uncertain ROB, or low ROB. Three inde-
pendent reviewers performed the quality assessment and dis-
agreements on scores were resolved through discussion.
2.6. Data analysis
The mean difference (MD) was used with 95% conﬁdence in-
tervals (CI) and standard deviation (SD). A meta-analysis was
conducted with simultaneous use of ﬁxed-effect and random-effect
models. All statistical analyses were performed using RevMan V.5.1
(Cochrane Collaboration, Oxford, UK) software. The meta-analysis
included data from parallel-group design studies. Although the
studies contained multiple time point observations and different
dosages, the intervention dosages were relatively similar: three
studies used 3 g/day and one study used 1.6 g/day. However, the
duration of studies was substantially different and the RCTs were
subdivided into shorter versus longer periods (30 days or > 30
days). Since the data used for the meta-analysis were continuous
variables such as fasting serum glucose and insulin levels, HbA1c,
and HOMA-IR, the MD and SD were used for meta-analysis. Het-
erogeneity of the included studies was tested with the Higgins I2
test and meaningful heterogeneity was determined by 50% of the I2
value. When the I2 value was >50, a random-effect model was used
for the meta-analysis. Funnel plots were used to detect reporting
biases for this systematic review since the number of studies
induced was <10 studies.
2.7. Subgroup analysis
The duration of the studies was as follows: one study (30 days);
two studies (8 weeks); and two studies (12 weeks). RCTs were
subdivided into shorter versus longer periods (30 days
versus > 30 days). However,  30 days was only one group;
therefore the analysis was conducted without the RCT of 30 days
duration.
3. Results
3.1. Summary of included studies
An initial electronic search found a total of 869 studies. A total of
853 studies were excluded (177 in vitro experiments, 376 animal
experiments, and 300 ginger and similar plant related studies). Of
the remaining 15 studies ﬁve duplicate studies were removed.
Finally, ﬁve RCTs met the inclusion criteria after removing two RCTs
not related to ginger and three RCTs in which participants did not
have Type 2 diabetes mellitus (Fig. 1). The ﬁve remaining RCTs were
used for meta-analysis [12e16]. The main data from the included
RCTs were summarized in Table 1. Surprisingly, four RCTs were
conducted in Iran and one in India although ginger is commonly
Fig. 1. Selection process of the randomized clinical trials (RCTs).
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design (ginger powder and placebo groups) and one RCT adopted a
four-arm parallel design including ginger powder, two other herbs,
and a placebo group.
3.2. Risk of bias
The ROB assessment for the included RCTs is presented in
Table 2. Of the ﬁve RCTs identiﬁed for analysis in this study, four
were classiﬁed as high quality and one as low quality [12e16]. Four
studies used a proper randomization of participants such as coin
ﬂipping and computer generated random numbers [12e14,16] but
one study was considered low quality as it did not describe how the
participants were randomized [15]. In addition, four RCTs used
blinding of participants and practitioners [14e16,18], blinding was
not mentioned in the one low quality RCT. Drop-out rates were not
high in any of the RCTs, four RCTs recorded the reasons for with-
drawal where applicable [14e16,18].
3.3. Outcomes
Type 2 diabetes statuses were determined by fasting serum
levels of glucose, HbA1c (the index of long-term serum glucose
control), insulin, and HOMA-IR (the index of insulin resistance).
Three RCTs determined all four variables [14e16,18] and one RCT
measured fasting serum glucose levels and HbA1c in Type 2 dia-
betic patients [17]. In the one remaining RCT, only fasting serum
glucose levels were measured. The pooled summary effects of
fasting serum glucose levels for all ﬁve RCTs and then for the four
RCTs with longer periods are provided in Fig. 2A and Fig. 2B. Four
RCTs reported lower fasting serum glucose levels in the ginger
supplemented group in comparison to the placebo group. However,
RCTs showed no improvement in the glucose levels in the ginger
group. The MDs of the levels observed tended to be lower in the
ginger group (n ¼ 123) than the placebo group (n ¼ 120) but it wasnot signiﬁcantly different in meta-analysis (p¼ 0.07). However, the
MDs were signiﬁcantly lower in the ginger group for all ﬁve RCTs
(n ¼ 131) than the placebo group (n ¼ 128) (p ¼ 0.009).
HbA1c levels in the circulation of Type 2 diabetic patients were
signiﬁcantly decreased in all four RCTs in which the levels were
measured. The 95% CI of MDs of four RCTs were [2.04, 1.29]
(p < 0.001) (Fig. 2C). This indicated that there was a signiﬁcant
difference between the ginger (n ¼ 123) and placebo (n ¼ 120)
groups, suggesting that ginger had a long-term serum glucose
lowering effect.
When pooling the three RCTs that measured fasting serum in-
sulin levels, the MDs were not signiﬁcantly different between the
ginger (n ¼ 101) and placebo groups (n ¼ 101) (p ¼ 0.17) (Fig. 2D).
Furthermore, the MDs of HOMA-IR, when pooling three RCTs were
also not signiﬁcantly different between the ginger and placebo
groups (p ¼ 0.17) (Fig. 2F). Ginger supplementation may prevent
increased fasting serum insulin levels and HOMA-IR, this could be
determined if the sample size was as large as it was for fasting
serum glucose levels. Therefore, it is possible, but not well estab-
lished, that ginger improves fasting serum glucose levels
and HbA1c by decreasing insulin resistance in Type 2 diabetic
patients.
3.4. Adverse events
Four RCTs did not report any adverse effects; one RTC did report
an adverse event. Arablou et al [14] reported that one patient out of
33 in the ginger treated group had heartburn after taking the
supplement.
4. Discussion
This review found that studies administering 1,600e3,000mg of
ginger powder per day for 8e12 weeks lowered fasting serum
glucose levels and HbA1c levels in patients with Type 2 diabetes.
Table 1
The Summaries of Five Randomized Clinical Trials to Investigate the Effects of Ginger Supplementation on Type 2 Diabetic patients.
First author (y) [Ref.]
(country to conduct
the study)
Study design No. & characteristics
of patients / FPG
Eligibility criteria of
subjects
Exclusion criteria
of subjects
Included Experimental
intervention / use
level / treatment
duration
Control
intervention / use
level / treatment
duration
FPG result
1. FPG
2. HbA1c
3. Insulin
4. HOMA
Effect size
1. FPG
2. HbA1c
3. insulin
4. HOMA
Author's
conclusions
Adverse
events
Arablou et al (2014)
[14] (Iran)
RCT with two
parallel groups
70 DM2 patients /
FPG 88.5~191.2 mg/dL
30e70 y
Treated with oral
hypoglycemic agents,
HbA1c between 7% and
10%, BMI between
20 kg/m2 and 35 kg/m2,
no pregnancy or
lactation, no use of
tobacco or alcohol, no
renal, liver, thyroid and
parathyroid disorders,
cancer, infection,
inﬂammation and fever
Ginger (n ¼ 2)
Heartburn (n ¼ 1)
Unwilling to
cooperate (n ¼ 1)
Placebo (n ¼ 5)
1. Unwilling to
cooperate (n ¼ 3)
2. Pregnancy
(n ¼ 1)
3. Recurrence of
disease and the
need for insulin
therapy (n ¼ 1)
1. Ginger
(n ¼ 33)
2. Placebo
(n ¼ 30)
Ginger powder
capsule before
lunch & dinner
800 mg 12 wks
Wheat ﬂour
powder capsule
before lunch &
dinner
800 mg 12 wks
1. (p ¼ 0.02)
2. (p ¼ 0.001)
3. (p ¼ 0.001)
4. (p ¼ 0.001)
1. 9.1
2. 1.0
3. 3.7
4. 1.7
Ginger can reduce
blood glucose and
insulin levels and
improve insulin
sensitivity in DM2
patients.
(n ¼ 1)
heartburn
Mozaffari-Khosravi
et al
(2014) [15] (Iran)
RCT with two
parallel groups
88 DM2 patients /
FPG 95.64~226.21
mg/dL
Having DM2 for at least
10 y, Fasting blood
glucose <180 mg/dL
and 2h blood-sugar
<250 mg/dL, no
pregnancy or lactation,
no autoimmune
disorder, no cardiac
ischemic or renal
diseases, no thyroid and
chronic inﬂammatory
diseases, peptic ulcer
and infection, no
regular consumption of
ginger or other herbal
drugs, no sensitivity to
ginger, BMI <40 kg/m2,
no consumption of
triglycerides or
cholesterol-, estrogen-,
or progesterone-
lowering drugs, and no
consumption of any
supplements such as
vitamin C, vitamin E,
and omega 3 for 2 m
before starting the
research.
Ginger
1. Lost to follow-
up (n ¼ 2)
2. Discontinued
intervention
(n ¼ 2)
Placebo
1. Lost to follow-
up (n ¼ 2)
2. Discontinued
intervention
(n ¼ 1)
1. Ginger
(n ¼ 40)
2. Placebo
(n ¼ 41)
Ginger powder
capsule
Three meals /
1,000 mg 8 wks
Microcrystalline
cellulose capsule
Three meals /
1,000 mg 8 wks
1. (p < 0.005)
2. (p < 0.005)
3. (p < 0.005)
4. (p < 0.005)
1 .18.17
2. 0.4
3. 7.4
4. 1.02
Ginger lowered FBS
and HbA1c mean
values as well as
variation in fasting
insulin, insulin
resistance, increase
of sensitivity to
insulin and the
QUICKI
nr
Mahluji et al (2013)
[16] (Iran)
RCT with two
parallel groups
64 DM2 patients /
FPG 106~200 mg/dl
38e65 y
Insulin therapy at
baseline or throughout
the study, no smoking,
pregnancy or
breastfeeding, no
taking any herbal
plants as a home
remedy or as a
supplement within the
previous 3 w or
throughout the study,
Ginger
Treatment failure
(n ¼ 2)
Travel (n ¼ 1)
Medication
changing (n ¼ 1)
Placebo
1. Treatment
failure (n ¼ 1)
2. Travel (n ¼ 1)
Ginger
(n ¼ 28)
2. Placebo
(n ¼ 30)
Ginger powder
capsule. Three
meals / 1,000 mg
8 wks
Cornstarch tablet.
Three
meals / 1,000 mg
8 wks
1. (p ¼ 0.425)
2. (p ¼ 0.664)
3. (p ¼ 0.001)
4. (p ¼ 0.002)
1. 6.1
2. 3.5
3. 13
4. 8.1
Oral ginger
supplementation
decreased the
levels of insulin in
patients with DM2
without a
signiﬁcant effect on
fasting plasma
glucose and HbA1c.
nr
(continued on next page)
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Table 1 (continued )
First author (y) [Ref.]
(country to conduct
the study)
Study design No. & characteristics
of patients / FPG
Eligibility criteria of
subjects
Exclusion criteria
of subjects
Included Experimental
intervention / use
level / treatment
duration
Control
intervention / use
level / treatment
duration
FPG result
1. FPG
2. HbA1c
3. Insulin
4. HOMA
Effect size
1. FPG
2. HbA1c
3. insulin
4. HOMA
Author's
conclusions
Adverse
events
no acute illnesses or
having kidney, liver,
gallbladder or thyroid
disorders,
inﬂammatory intestinal
diseases and
immunodeﬁciency
diseases.
Andallu et al (2001)
[17]
(India)
RCT with four
parallel groups
32 DM2
hypercholesterolemic
patients / FPG
106~200 mg/dL
40e60.5 y
Diabetics and
hypercholesterolemic
nr 1. Ginger
(n ¼ 8)
2. Placebo
(n ¼ 8)
Ginger powder
capsules. Six
capsules (two
after a meal) /
500 mg/30 d
Six corn starch
capsules (two
after a meal)/
500 mg/30 d
1. p < 0.01 1. 12 Aswagandha,
ginger and
mulberry appear to
be effective in
lowering blood
glucose and serum
lipid levels.
nr
Khandouzi et al
(2015) [18] (Iran)
RCT with two
parallel groups
64 DM2 patients /
FPG 73.17~237.3 mg/dL
20e60 y
Disease duration at
least 2 y, HbA1c level of
6e8%, taken with no
antioxidant
supplements such as
selenium, zinc and
beta-carotene for at
least 3 m prior to the
study, no smoking or
drinking.
Ginger
1. Lost to follow-
up (n ¼ 1)
2. Discontinued
intervention
(n ¼ 1)
3. Excluded from
analysis (n ¼ 1)
Placebo
1. Lost to follow-
up (n ¼ 1)
2. Discontinued
intervention
(n ¼ 2)
3. Excluded from
analysis (n ¼ 3)
1. Ginger
(n ¼ 22)
2. Placebo
(n ¼ 19)
Per 1g Ginger
powder capsule /
twice daily / 12 w
Per 1g Lactose
powder capsule /
twice daily / 12 w
p ¼ 0.000
p ¼ 0.000
1. 19
2. 0.77
Ginger
supplementation
signiﬁcantly
reduced the levels
of FBS, HbA1c,
Apo B, Apo B /
Apo A-I and
malonyldialdehyde
(MDA), and
increased the level
of Apo A-I in DM2
patients.
nr
Apo, apolipoprotein; BMI, body mass index; bw, body weight; DM2, type 2 diabetes mellitus; FBS, fasting blood sugar; FPG, Fasting plasma glucose; HbA1c, hemoglobin A1c; HOMA, homeostatic model assessment; MDA; nr, not
reported; QUICKI, quantitative insulin sensitivity check index; RCT, randomized controlled trial.
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Table 2
Risk of Bias in Included Trials.
Random
sequence
generation
Allocation
concealment
Patient &
practitioner
blinding
Assessor
blinding
Reporting
drop-out or
withdrawal
Intention-to
treat analysis
Selective
outcome
reporting
Other potential
bias
Arablou et al (2014) [14] L L L L L U U U
Mozaffari-Khosravi et al (2014) [15] L L L L U L U U
Mahluji et al (2013) [16] L L L L U L U L
Andallu et al (2001) [17] H H H H U U U U
Khandouzi et al (2015) [18] L L L U L L U U
H, high risk of bias; L, low risk of bias, U, uncertain risk of bias.
Fig. 2. Forest plot of ginger showing its effectiveness in treating Type 2 diabetes mellitus. (A) For fasting serum glucose levels with short-term study. (B) For fasting serum glucose
levels without short-term study. (C) For hemoglobin A1C levels in four studies. (D) For fasting serum insulin levels in three studies. (E) For HOMA-IR in three studies.
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sulin levels and HOMA-IR, an index of insulin resistance, but they
were not signiﬁcantly different in Type 2 diabetic patients. Thus,
ginger supplementation improves glucose homeostasis in Type 2
diabetic patients possibly by lowering insulin resistance although
the mechanism remains uncertain since neither the decreased in-
sulin levels nor HOMA-IR reached statistical signiﬁcance. This could
be due to insufﬁcient power of the meta-analysis since only four
relatively small studies were available.
The studies included in the meta-analysis were quite homoge-
neous. All studies were conducted in Iran and all participating pa-
tients had Type 2 diabetes. Most of studies were conducted for
8e12 weeks and one study was conducted over 30 days. In this
study, only fasting serum glucose levels were measured so this
study was not included with longer duration studies, only fasting
serum glucose levels were reviewed and reported. The Andallu et al
[17] study supports the current evidence base from the human,
animal, and cellular studies that suggest a therapeutic beneﬁt of
ginger for lowering fasting serum glucose levels in Type 2 diabetic
patients. The mechanism by which ginger improves glucose toler-
ance remains uncertain and even which bioactive compound in
ginger is responsible for its antidiabetic efﬁcacy is unknown,
although it likely that 6-gingerol, the predominant pungent com-
pound in ginger, is responsible for its beneﬁts [2,6]. Some studies
have also shown that Type 2 diabetic rats fed ginger or gingerol
exhibit improved glucose regulation, insulin secretion, and lipid
proﬁles [19,20]. However, there are numerous bioactive com-
pounds in ginger, many of which may be responsible for the
numerous health beneﬁts attributed to ginger [20]. Many of the
putative activities of ginger (antioxidant, anti-inﬂammatory, hep-
atoprotective, antiobesity) are often associated with the etiology
and pathophysiology of Type 2 diabetes, which suggests the pos-
sibility that ginger may not have a direct effect on diabetes but acts
indirectly by suppressing factors that lead to impaired glucose
control. This was supported by a study showing that ginger root
powder (200 mg/kg body weight) in a Type 2 diabetic rat model
reversed symptoms of metabolic syndrome, blood glucose, blood
lipids, and decreased oxidative stress [21].
The indirect methods by which ginger might protect against
diabetes would be mostly applicable to Type 2 diabetes; however,
there is evidence to support direct efﬁcacy of ginger in Type 1
diabetes as well [22]. Ojewole [23] found that a ginger extract
(100e800 mg/kg body weight) lowered blood glucose levels by
24e58% in Type 1 diabetic rats. Another study of streptozotocin-
induced Type 1 diabetic rats found that 500 mg/kg body weight
per day of an aqueous ginger extract experienced decreased blood
glucose levels by 38% and 68% after 15 days and 30 days, respec-
tively [24]. In that study ginger also increased muscle and liver
glycogen stores in the diabetic rats and increased the activities of
glucokinase, phosphofructokinase and pyruvate kinase. Finally,
insulin-independent gingerol stimulation of glucose uptake was
demonstrated in L6 rat skeletal muscle cells, which was attributed
to an increased translocation of the GLUT4 glucose transporter the
plasma membrane surface of the cells [25]. These studies strongly
suggest a direct effect of ginger and gingerols in the treatment of
diabetes.
This meta-analysis along with the supporting evidence from
animal and cellular studies strongly suggests that ginger has efﬁ-
cacy for the management of blood glucose levels and that the ef-
fects are both preventive and therapeutic for Type 2 diabetes.
Findings also suggest that ginger can directly increase glucose up-
take in an insulin-independent manner that may be beneﬁcial in
the management of both Type 1 and Type 2 diabetes.
The major limitation of this study was the relatively few clinical
trials available for the meta-analysis and the modest number ofparticipants in each trial. However, that was offset by the consis-
tency of the results in which, regardless of the statistical signiﬁ-
cance of the individual studies, none of them showed an increase in
blood glucose levels due to ginger consumption and all of them
showed a least a modest decrease in blood glucose levels. The po-
wer of the combined data clearly demonstrated that ginger can
lower blood glucose and HbA1c levels in humans. Also of impor-
tance was the demonstration that a manageable dose of ginger
powder can be effective. However, further studies carefully evalu-
ating dose-dependency are needed to clearly establish what dosage
provides the greatest efﬁcacy for the treatment of diabetes. The
safety of long-term ginger consumption may need to be further
evaluated; however, the safety of ginger use for treating nausea
during pregnancy has been evaluated in human studies at doses up
to 2,500 mg/day, and demonstrated to be safe for use during
pregnancy [10,26].
In conclusion, this meta-analysis provides convincing evidence
to support the efﬁcacy of ginger in the management of Type 2
diabetes.Conﬂicts of interest
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